Ion Channels Induced by the Prion Protein: Mediators of Neurotoxicity

Overview

Journal Prion

Specialty Biochemistry

Date 2012 Mar 29

PMID 22453177

Citations 20

Authors

Isaac H Solomon

Emiliano Biasini

David A Harris

Affiliations

Soon will be listed here.

Abstract

Prion diseases comprise a group of rapidly progressive and invariably fatal neurodegenerative disorders for which there are no effective treatments. While conversion of the cellular prion protein (PrP(C)) to a β-sheet rich isoform (PrP(Sc) ) is known to be a critical event in propagation of infectious prions, the identity of the neurotoxic form of PrP and its mechanism of action remain unclear. Insights into this mechanism have been provided by studying PrP molecules harboring deletions and point mutations in the conserved central region, encompassing residues 105-125. When expressed in transgenic mice, PrP deleted for these residues (Δ105-125) causes a spontaneous neurodegenerative illness that is reversed by co-expression of wild-type PrP. In cultured cells, Δ105-125 PrP confers hypersensitivity to certain cationic antibiotics and induces spontaneous ion channel activity that can be recorded by electrophysiological techniques. We have utilized these drug-hypersensitization and current-inducing activities to identify which PrP domains and subcellular locations are required for toxicity. We present an ion channel model for the toxicity of Δ105-125 PrP and related mutants and speculate how a similar mechanism could mediate PrP(Sc)-associated toxicity. Therapeutic regimens designed to inhibit prion-induced toxicity, as well as formation of PrP(Sc) , may prove to be the most clinically beneficial.

Citing Articles

A unified model for the origins of spongiform degeneration and other neuropathological features in prion diseases.

Schmitt-Ulms G, Wang X, Watts J, Booth S, Wille H, Zhao W ArXiv. 2025; .

PMID: 39876936 PMC: 11774453.

Mechanisms of prion-induced toxicity.

Mercer R, Harris D Cell Tissue Res. 2022; 392(1):81-96.

PMID: 36070155 DOI: 10.1007/s00441-022-03683-0.

Identification of noble candidate gene associated with sensitivity to phytotoxicity of etofenprox in soybean.

Kim J, Ha J, Shin I, Lee J, Park J, Lee J Sci Rep. 2022; 12(1):14944.

PMID: 36056125 PMC: 9440009. DOI: 10.1038/s41598-022-19323-0.

Antibody binding modulates the dynamics of the membrane-bound prion protein.

Ilie I, Bacci M, Vitalis A, Caflisch A Biophys J. 2022; 121(14):2813-2825.

PMID: 35672948 PMC: 9382331. DOI: 10.1016/j.bpj.2022.06.007.

Neurometals in the Pathogenesis of Prion Diseases.

Kawahara M, Kato-Negishi M, Tanaka K Int J Mol Sci. 2021; 22(3).

PMID: 33525334 PMC: 7866166. DOI: 10.3390/ijms22031267.

References

Shyng S, Heuser J, Harris D . A glycolipid-anchored prion protein is endocytosed via clathrin-coated pits. J Cell Biol. 1994; 125(6):1239-50. PMC: 2290925. DOI: 10.1083/jcb.125.6.1239. View

Resenberger U, Harmeier A, Woerner A, Goodman J, Muller V, Krishnan R . The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J. 2011; 30(10):2057-70. PMC: 3098494. DOI: 10.1038/emboj.2011.86. View

Harris D, True H . New insights into prion structure and toxicity. Neuron. 2006; 50(3):353-7. DOI: 10.1016/j.neuron.2006.04.020. View

Warner R, Hundt C, Weiss S, Turnbull J . Identification of the heparan sulfate binding sites in the cellular prion protein. J Biol Chem. 2002; 277(21):18421-30. DOI: 10.1074/jbc.M110406200. View

Telling G, Haga T, Torchia M, Tremblay P, DeArmond S, Prusiner S . Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. Genes Dev. 1996; 10(14):1736-50. DOI: 10.1101/gad.10.14.1736. View

Parkin E, Watt N, Turner A, Hooper N . Dual mechanisms for shedding of the cellular prion protein. J Biol Chem. 2004; 279(12):11170-8. DOI: 10.1074/jbc.M312105200. View

Norstrom E, Mastrianni J . The AGAAAAGA palindrome in PrP is required to generate a productive PrPSc-PrPC complex that leads to prion propagation. J Biol Chem. 2005; 280(29):27236-43. DOI: 10.1074/jbc.M413441200. View

Lauren J, Gimbel D, Nygaard H, Gilbert J, Strittmatter S . Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009; 457(7233):1128-32. PMC: 2748841. DOI: 10.1038/nature07761. View

Christensen H, Dikranian K, Li A, Baysac K, Walls K, Olney J . A highly toxic cellular prion protein induces a novel, nonapoptotic form of neuronal death. Am J Pathol. 2010; 176(6):2695-706. PMC: 2877832. DOI: 10.2353/ajpath.2010.091007. View

10.

Holscher C, Delius H, Burkle A . Overexpression of nonconvertible PrPc delta114-121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc) accumulation. J Virol. 1998; 72(2):1153-9. PMC: 124590. DOI: 10.1128/JVI.72.2.1153-1159.1998. View

11.

Massignan T, Stewart R, Biasini E, Solomon I, Bonetto V, Chiesa R . A novel, drug-based, cellular assay for the activity of neurotoxic mutants of the prion protein. J Biol Chem. 2009; 285(10):7752-65. PMC: 2844219. DOI: 10.1074/jbc.M109.064949. View

12.

Christensen H, Harris D . A deleted prion protein that is neurotoxic in vivo is localized normally in cultured cells. J Neurochem. 2008; 108(1):44-56. DOI: 10.1111/j.1471-4159.2008.05719.x. View

13.

Manson J, Jamieson E, Baybutt H, Tuzi N, Barron R, McConnell I . A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J. 1999; 18(23):6855-64. PMC: 1171748. DOI: 10.1093/emboj/18.23.6855. View

14.

Yang W, Cook J, Rassbach B, Lemus A, DeArmond S, Mastrianni J . A New Transgenic Mouse Model of Gerstmann-Straussler-Scheinker Syndrome Caused by the A117V Mutation of PRNP. J Neurosci. 2009; 29(32):10072-80. PMC: 2749997. DOI: 10.1523/JNEUROSCI.2542-09.2009. View

15.

Race R, Raines A, Raymond G, Caughey B, Chesebro B . Long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: analogies to bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in humans. J Virol. 2001; 75(21):10106-12. PMC: 114584. DOI: 10.1128/JVI.75.21.10106-10112.2001. View

16.

Massignan T, Biasini E, Harris D . A Drug-Based Cellular Assay (DBCA) for studying cytotoxic and cytoprotective activities of the prion protein: A practical guide. Methods. 2010; 53(3):214-9. PMC: 3384733. DOI: 10.1016/j.ymeth.2010.11.005. View

17.

Taylor D, Whitehouse I, Hooper N . Glypican-1 mediates both prion protein lipid raft association and disease isoform formation. PLoS Pathog. 2009; 5(11):e1000666. PMC: 2773931. DOI: 10.1371/journal.ppat.1000666. View

18.

Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y . Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 1996; 379(6563):339-43. DOI: 10.1038/379339a0. View

19.

Marcotti W, van Netten S, Kros C . The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-electrical transducer channels. J Physiol. 2005; 567(Pt 2):505-21. PMC: 1474200. DOI: 10.1113/jphysiol.2005.085951. View

20.

Dossena S, Imeri L, Mangieri M, Garofoli A, Ferrari L, Senatore A . Mutant prion protein expression causes motor and memory deficits and abnormal sleep patterns in a transgenic mouse model. Neuron. 2008; 60(4):598-609. DOI: 10.1016/j.neuron.2008.09.008. View